TRD News & Analysis
1 article
Market Mood
0 Bullish0 Neutral1 Bearish
Morgan Stanley Lowers Compass Pathways Stock Price Target Amid TRD Progress
Morgan Stanley has reduced its stock price target for Compass Pathways to $X from $Y, citing progress in development for treatments related to TRD (treatment-resistant depression). The update reflects changing expectations related to the company's clinical trials and market potential. This adjustment may impact investor sentiment and trading volumes for Compass Pathways shares.
Read More